PBH Prestige Consumer Healthcare Inc

Prestige Consumer Healthcare Inc. to Release Fiscal 2021 Fourth Quarter and Year-End Earnings Results

Prestige Consumer Healthcare Inc. to Release Fiscal 2021 Fourth Quarter and Year-End Earnings Results

TARRYTOWN, N.Y., April 08, 2021 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2021 fourth quarter and year-end earnings release on Thursday, May 6, 2021 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET.

To participate via phone listeners calling from the U.S. and Canada may dial 844-233-9440, or 574-990-1016 internationally, using the conference ID 5996287. The Company will provide a live Internet webcast as well as an archived replay, which can be accessed from the Investor Relations page of

Telephonic replays will be available for approximately one week following completion of the live call and can be accessed at 855-859-2056 within North America, and at 404-537-3406 from outside North America. The conference ID is 5996287.

About Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare markets, sells, manufactures and distributes consumer healthcare products to retail outlets throughout the U.S. and Canada, Australia, and in certain other international markets. The Company’s diverse portfolio of brands include Monistat® and Summer’s Eve® women's health products, BC® and Goody's® pain relievers, Clear Eyes® eye care products, DenTek® specialty oral care products, Dramamine® motion sickness treatments, Fleet® enemas and glycerin suppositories, Chloraseptic® and Luden's® sore throat treatments and drops, Compound W® wart treatments, Little Remedies® pediatric over-the-counter products, Boudreaux’s Butt Paste® diaper rash ointments, Nix® lice treatment, Debrox® earwax remover, Gaviscon® antacid in Canada, and Hydralyte® rehydration products and the Fess® line of nasal and sinus care products in Australia. Visit the Company's website at

Investor Relations Contact

Phil Terpolilli, CFA, 914-524-6819



EN
08/04/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Prestige Consumer Healthcare Inc

 PRESS RELEASE

Dramamine® Celebrates its 75th Anniversary by Reviving an Unexpected P...

Dramamine® Celebrates its 75th Anniversary by Reviving an Unexpected Partner: The Barf Bag The nausea-fighting brand is highlighting the cultural impact of barf bags and ushering them into a new era with a documentary, a limited-edition collection of upcycled bags and a custom wearable art piece made from vintage bags TARRYTOWN, N.Y., April 03, 2024 (GLOBE NEWSWIRE) -- 1949 was a big year for barf, welcoming the invention of the barf bag and . Seventy-five years later, Dramamine, a Prestige Consumer Healthcare brand, thrives as the number one brand for motion sickness relief, but as Dr...

Prestige Consumer Healthcare Inc: 2 directors

Two Directors at Prestige Consumer Healthcare Inc sold after exercising options/sold 56,038 shares at between 67.899USD and 68.353USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary ...

 PRESS RELEASE

Prestige Consumer Healthcare Inc. Reports Third Quarter Fiscal 2024 Re...

Prestige Consumer Healthcare Inc. Reports Third Quarter Fiscal 2024 Results Revenue of $282.7 Million in Q3, Up 2.6% Versus Prior YearDiluted EPS of $1.06 in Q3, Up 2.2% Versus Prior YearReduced Leverage Ratio to 2.9x at Quarter EndRaising Full-Year Fiscal 2024 Earnings Outlook to Approximately $4.33 TARRYTOWN, N.Y., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its third quarter and first nine months ended December 31, 2023. “We are pleased with our continued strong results that exceeded our revenue and earnings expe...

 PRESS RELEASE

Insight Pharmaceuticals Issues Voluntary Nationwide Recall of TING® 1%...

Insight Pharmaceuticals Issues Voluntary Nationwide Recall of TING® 1% Tolnaftate Athlete’s Foot Spray Antifungal Spray Liquid Due to the Presence of Benzene TARRYTOWN, N.Y., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Insight Pharmaceuticals, a Prestige Consumer Healthcare Inc. company (“Insight”), is voluntarily recalling two lots of TING® 1% Tolnaftate Athlete’s Foot Spray Antifungal Spray Liquid to the consumer level. A recent review by our manufacturer and their third-party lab found that samples from two lots of the product contained elevated levels of benzene. While benzene is not an ingredi...

 PRESS RELEASE

Prestige Consumer Healthcare Inc. to Release Fiscal 2024 Third Quarter...

Prestige Consumer Healthcare Inc. to Release Fiscal 2024 Third Quarter Earnings Results TARRYTOWN, N.Y., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2024 third quarter earnings release on Thursday, February 8, 2024 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of . To participate in the conference call v...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch